It will also be important to assess whether similar proteostatic pathway changes are found in mismatch cases in other neurodegenerative diseases, such as AD, in which some diagnosed patients are known to have low levels of CSF Abeta, but no Abeta accumulation is visible in positron emission tomography (Mattsson et al., 2015). This evidence concerns the gene APP and Alzheimer disease.